Related Experiment Video
Updated: Jun 6, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Intrinsic resistance to chemotherapy in breast cancer
1Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. smoulder@mdanderson.org
Abstract:
Systemic therapy improves disease-free survival in patients with breast cancer, but does not cure patients with advanced or metastatic disease, and fails to benefit the majority of patients with localized breast cancer. Intrinsic resistance to chemotherapy is emerging as a significant cause of treatment failure and evolving research has identified several potential causes of resistance, such as drug efflux pumps, disregulation of apoptosis and cancer stem cells. Building upon preclinical models, drugs designed to reverse resistance to therapy are currently under investigation in clinical trials for the treatment of breast cancer.
Insights
Systemic therapy offers limited benefits for advanced breast cancer and fails many localized cases. Research is exploring ways to overcome chemotherapy resistance, with new drugs in clinical trials.
Area of Science:
- Oncology
- Pharmacology
Background:
- Systemic therapy improves survival in breast cancer but does not cure advanced disease.
- Chemotherapy resistance is a major cause of treatment failure in breast cancer.
- Mechanisms of resistance include drug efflux pumps, apoptosis dysregulation, and cancer stem cells.
Purpose of the Study:
- To investigate the causes of intrinsic chemotherapy resistance in breast cancer.
- To explore novel therapeutic strategies targeting resistance mechanisms.
Main Methods:
- Review of preclinical models and existing research on chemotherapy resistance.
- Identification of key molecular mechanisms contributing to resistance.
- Analysis of ongoing clinical trials for drugs targeting resistance.
Main Results:
- Intrinsic resistance significantly impacts treatment outcomes in breast cancer.
- Several molecular targets and pathways are implicated in chemotherapy resistance.
- Clinical trials are evaluating drugs designed to reverse these resistance mechanisms.
Conclusions:
- Overcoming chemotherapy resistance is crucial for improving breast cancer treatment efficacy.
- Targeting resistance mechanisms holds promise for future breast cancer therapies.
- Ongoing clinical investigations are vital for advancing treatment options.
More Related Videos
09:58Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Treatment Resistant Cancers
The Intrinsic Apoptotic Pathway
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase